Psychiatry

In a "secret shopper" study, investigators posing as Medicaid enrollees found many clinicians in Medicaid provider directories do not accept Medicaid insurance.

A year after zuranolone’s FDA approval for postpartum depression on August 3, 2023, prescribers and a patient weigh in about the medication’s success in alleviating symptoms.

This month in review captures the top news in the psychiatry field during July.

This extended-release injectable suspension for schizophrenia and schizoaffective disorder is approved as a monotherapy and as an adjunct to mood stabilizers or antidepressants.

A new study found using e-cigarettes with partial nicotine reduction was linked to greater puffing time, puff duration, and total inhaled volume than 5% nicotine concentration.

A new study found the group with the shortest seizure duration of ≤ 20 seconds had the lowest remission rate of 27.2%, compared with a 39.3% overall remission rate.

Depression A new study discovers a dual pathway framework where antidepressants are concomitantly negatively and positively linked to alcohol use.

A study found wearable devices alerting irregular heart rhythms amplified anxiety in 1 in 5 participants with atrial fibrillation, which led people to be more likely to seek care.

A new study found claims for services of opioid treatment programs rose among Medicare beneficiaries after Medicare started covering them.

A new study found probable PTSD was prevalent among adults in the community after a mass shooting, with greater prevalence among those previously assaulted.

In this part of our 5-part series, Gus Alva, MD discusses the next steps in research for long-term effects and broader applications of MDMA-assisted therapy.

In this part of our 5-part series, Gus Alva, MD explores MDMA’s neurochemical impact and the need for ongoing research.

In this part of our 5-part series, Gus Alva, MD highlights the importance of education and overcoming skepticism about MDMA-assisted therapy.

In this part of our 5-part series, Gus Alva, MD talks about MDMA's efficacy in controlled settings and addresses misconceptions.

In this part of our 5-part series, Gus Alva, MD discusses the unmet need in PTSD treatment and the potential of MDMA-assisted therapy.

A study demonstrated a smartphone app provides comparable benefits to cognitive behavior or mindfulness-based therapy, widening the supply gap for mental health care.

A new study found a high adherence to a healthy prenatal dietary pattern was associated with a 22% reduced likelihood of an offspring autism diagnosis.

Schizophrenia experts discuss the stigma and misconceptions surrounding schizophrenia as well as current treatment options.

A study found children and young adults with cerebral palsy have more anxiety and less depression than those with a chronic condition or who are typically developed.

A study shows it is safer for nursing home residents on CYP2D6 opioids to take CYP2D6-neutral antidepressants than CYP2D6-inhibiting antidepressants.

Johnson & Johnson submits a supplemental New Drug Application to the FDA for the approval of esketamine as a monotherapy for adults with treatment-resistant depression.

A new study found individuals with depression and anxiety have a high prevalence of medical debt.

A new study confirms GLP-1RAs do not increase the risk for suicidal thoughts or behaviors, aligning with the FDA findings.

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

Dunlop discusses what the next steps for MDMA-assisted therapy would be if approved.